Page 17 - Research In Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tiziana Life Sciences Ltd : Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Life Sciences Ltd : Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Irina kofflerPaul spencerResearch in multiple sclerosisResearch of multiple sclerosisTiziana life sciences ltdEuropean committee for treatmentLifesci advisorsBusiness developmentTiziana life sciencesSix non active secondary progressiveEuropean committeeMultiple sclerosisLife sciencesInvestor relationsSci advisorsAktien sie

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbJeffrey cohenRoland chenMellen centerResearch in multiple sclerosisNeurological instituteBristol myersMyers squibbAmericas committeesMultiple sclerosisMultiple sclerosis treatmentCleveland clinic

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Irina kofflerPaul spencerTiziana life sciences ltdResearch in multiple sclerosisResearch of multiple sclerosisBusiness developmentTiziana life sciencesLifesci advisorsEuropean committee for treatmentAnnounces presentationSix month safetyBiomarker dataIntranasal foralumabSix non active secondary progressiveLife sciencesEuropean committee

AstraZeneca : Alexion data at 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023) showcase impact of C5 inhibition in NMOSD -October 11, 2023 at 02:21 am EDT

Alexion, AstraZeneca Rare Disease, will present new data at MSMilan2023, the 9th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee.

United statesUnited kingdomChristophe hotermansOdense university hospitalResearch in multiple sclerosisHead of global medical affairsAlexion pharmaceuticals incMeeting of the european committee for treatmentAmericas committee for treatmentAstrazeneca rare diseaseJoint meetingEuropean committeeMultiple sclerosisAmericas committeeSenior vice presidentGlobal medical affairs

Genentech s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

Genentech s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

South san franciscoUnited statesLevi garrawayRoche groupProduct serviceResearch in multiple sclerosisGlobal product developmentOcrevus twice yearlyMinute subcutaneous injection was non inferiorIntravenous infusionProvided near complete suppressionAmericas committeesMultiple sclerosisGlobal productPeak ocrevusHalozyme therapeutic